Algarin Angel B, Plazarte Gabriela N, Sovich Kaitlin R, Seeger Stella D, Li Yancheng, Cohen Ronald A, Striley Catherine W, Goldberger Bruce A, Wang Yan, Somboonwit Charurut, Ibañez Gladys E, Spencer Emma C, Cook Robert L
Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Department of Psychology, University of South Florida, Tampa, CA, United States.
JMIR Res Protoc. 2022 Aug 30;11(8):e37153. doi: 10.2196/37153.
Marijuana use is common in persons with HIV, but there is limited evidence of its relationship with potential health benefits or harms.
The Marijuana Associated Planning and Long-term Effects (MAPLE) study was designed to evaluate the impact of marijuana use on HIV-related health outcomes, cognitive function, and systemic inflammation.
The MAPLE study is a longitudinal cohort study of participants living with HIV who were recruited from 3 locations in Florida and were either current marijuana users or never regular marijuana users. At enrollment, participants completed questionnaires that included detailed marijuana use assessments, underwent interviewer-administered neurocognitive assessments, and provided blood and urine samples. Ongoing follow-ups included brief telephone assessments (every 3 months), detailed questionnaires (annually), repeated blood and urine samples (2 years), and linkage to medical records and statewide HIV surveillance data. Supplemental measures related to intracellular RNA, COVID-19, Alzheimer disease, and the gut microbiome were added after study initiation.
The MAPLE study completed enrollment of 333 persons between 2018 and 2021. The majority of participants in the sample were ≥50 years of age (200/333, 60.1%), male (181/333, 54.4%), cisgender men (173/329, 52.6%), non-Hispanic Black (221/333, 66.4%), and self-reported marijuana users (260/333, 78.1%). Participant follow-up was completed in 2022, with annual updates to HIV surveillance data through at least 2027.
The MAPLE study is the largest cohort specifically designed to understand the use of marijuana and its effects on HIV-related outcomes. The study population has significant diversity across age, sex, gender, and race. The data will help clinicians and public health officials to better understand patterns of marijuana use associated with both positive and negative health outcomes, and may inform recommendations for future clinical trials related to medical marijuana and HIV.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/37153.
大麻在艾滋病毒感染者中使用很普遍，但关于其与潜在健康益处或危害之间关系的证据有限。
大麻相关规划与长期影响（MAPLE）研究旨在评估大麻使用对艾滋病毒相关健康结局、认知功能和全身炎症的影响。
MAPLE研究是一项纵向队列研究，研究对象为从佛罗里达州3个地点招募的艾滋病毒感染者，他们要么是当前的大麻使用者，要么从未经常使用过大麻。在入组时，参与者完成了包括详细大麻使用评估的问卷，接受了由访员进行的神经认知评估，并提供了血液和尿液样本。持续随访包括简短电话评估（每3个月一次）、详细问卷（每年一次）、重复采集血液和尿液样本（2年），以及与医疗记录和全州艾滋病毒监测数据的关联。在研究开始后增加了与细胞内RNA、COVID-19、阿尔茨海默病和肠道微生物群相关的补充措施。
MAPLE研究在2018年至2021年期间完成了333人的入组。样本中的大多数参与者年龄≥50岁（200/333，60.1%），男性（181/333，54.4%），顺性别男性（173/329，52.6%），非西班牙裔黑人（221/333，66.4%），以及自我报告的大麻使用者（260/333，78.1%）。参与者随访于2022年完成，艾滋病毒监测数据每年更新，至少持续到2027年。
MAPLE研究是专门为了解大麻使用及其对艾滋病毒相关结局的影响而设计的最大队列研究。研究人群在年龄、性别、性取向和种族方面具有显著多样性。这些数据将有助于临床医生和公共卫生官员更好地了解与积极和消极健康结局相关的大麻使用模式，并可能为未来与医用大麻和艾滋病毒相关的临床试验提供建议。
国际注册报告识别码（IRRID）：DERR1-10.2196/37153。
